劳拉替尼治疗携带ALK或ROS1基因重排非小细胞肺癌患者的首项全球多中心非盲单臂临床试验
The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement
劳拉替尼治疗携带ALK或ROS1基因重排非小细胞肺癌患者的首项全球多中心非盲单臂临床试验 |
| 评价者：杨衿记, 文献合成者：康劲 |
The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement |
| |